An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Renal Cancer

Inclusion Criteria:

The following patients may be eligible for this study:

- Histologically or cytologically documented evidence of epithelial renal cell
carcinoma with at least one measurable lesion (if previous radiation treatment, the
target lesion must have demonstrated progression since the radiation)

- Patients must have had a prior nephrectomy

- Must have a life expectancy of greater than three (3) months

- Patients who have had 0-1 prior cytokine treatment regimen (i.e. IL-2, IFN-?) or
relapsed less than one year after such treatment may be eligible.

Exclusion Criteria:

The following patients are not eligible for this study:

- Patients who have received more than one (1) prior cytokine regimen (i.e. IL-2, IFN?)
or relapsed more than one year after receiving such treatment are not eligible

- Patients who have had any prior chemotherapy (including a combination therapy)

- Patients with symptomatic CNS metastases or leptomeningeal involvement

- Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1

- Patients with severe cardiac insufficiency

- Patients taking Coumadin or other warfarin-containing agents with the exception of
low dose Coumadin (1 mg or less) for the maintenance of in-dwelling lines or ports

- History of another malignancy within 3 years prior to study entry except curatively
treated non-melanoma skin cancer, prostate cancer, or cervical cancer in situ

- Patients with active or suspected acute or chronic uncontrolled infection including
abcesses or fistulae

- HIV+ patients

- Pregnant or lactating females.